

The Discipline of Histopathology are delighted to invite you to the following presentations:

Respiratory viral infections and the acute and chronic impacts beyond the lung
by
Professor Stavros Selemidis
RMIT University Melbourne Australia

Biomarkers for prostate cancer; evidence base and prospects for commercialisation by

Professor Doug Brooks,

University of South Australia

Durkan Lecture Theatre

TTMI

Monday 22nd April 2024 10am-12pm



Professor Stavros Selemidis

Professor Stavros Selemidis is a pharmacologist and the head of the Oxidant and Inflammation Biology Group (OXIB) in the STEM College and School of Health and Biomedical Sciences (SHBS) at RMIT University. Stavros is also the CSO of the Biotech Company ViraLok Therapeutics Pty Ltd that he founded at RMIT. Stavros is internationally and nationally recognized for his fundamental and clinically translational research which aims to unravel novel disease paradigms and therapeutic targets for respiratory viruses including influenza (IAV), common cold and COVID-19 in humans and livestock industries.

https://www.rmit.edu.au/contact/staff-contacts/academic-staff/s/selemidis-stavros



Professor Doug Brooks

Professor Doug Brooks is the leader of the Mechanisms in Cell Biology and Disease Research Concentration in Clinical and Health Sciences Academic Unit and the Cancer Research Institute at the University of South Australia. Doug has over 30 years experience in medical research and is a Research Professor in Molecular Medicine at UniSA and Affiliate Professor of Cancer Pathology at Trinity College Dublin (TCD).

Professor Brooks is the Head Scientific Officer and a founding member of ReZolve Scientific, a molecular imaging and UniSA spin-out company. The main focus of Professor Brooks's research program is the development of novel biomarkers for cancer and the identification of novel companion diagnostics and theranostics.